	US 11,993,636 B2
	Antigenic OspA polypeptides
Gary J. Nabel, Bridgewater, NJ (US); Chih-Jen Wei, Bridgewater, NJ (US); Heather Kamp, Bridgewater, NJ (US); Ronnie Wei, Bridgewater, NJ (US); and Kurt Swanson, Bridgewater, NJ (US)
Assigned to SANOFI, Paris (FR)
Filed by Sanofi, Paris (FR)
Filed on Oct. 1, 2020, as Appl. No. 17/061,155.
Application 17/061,155 is a continuation of application No. PCT/US2019/025367, filed on Apr. 2, 2019.
Claims priority of provisional application 62/652,210, filed on Apr. 3, 2018.
Prior Publication US 2021/0017238 A1, Jan. 21, 2021
Int. Cl. C07K 14/20 (2006.01); C12N 15/10 (2006.01)

CPC C07K 14/20 (2013.01) [C12N 15/102 (2013.01)]

6 Claims

1. A composition comprising (a) an antigenic outer surface protein A (OspA) serotype 1 polypeptide of Borrelia and (b) a ferritin protein, wherein the OspA serotype 1 polypeptide of Borrelia does not comprise the sequence of SEQ ID NO: 77, wherein the OspA serotype 1 polypeptide of Borrelia comprises a sequence with at least 90% identity to the sequence of any one of SEQ ID NOS: 1, 3, 4, 53, or 94-102, and wherein the ferritin protein comprises a bullfrog linker that has the sequence of SEQ ID NO: 217, and wherein the ferritin protein comprises a sequence having at least 90% identity to SEQ ID NO: 90.